DNAI1 and primary ciliary dyskinesia: Most recently, ReCode Therapeutics, a genetic medicines company, announced the initiation of Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with PCD caused by pathogenic mutations in the DNAI1 gene, and first participants have been dosed to evaluate safety and tolerability of RCT1100 (https://recodetx.com/).